Rekah Pharmaceutical Industry Ltd (REKA) — Working Capital to Net Assets Ratio
Rekah Pharmaceutical Industry Ltd (REKA) has a Working Capital to Net Assets ratio of 56.0% as of December 2025. Working capital of ILA80.82 Million (current assets of ILA232.68 Million minus current liabilities of ILA151.87 Million) is measured against net assets of ILA144.21 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See REKA equity financing ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Rekah Pharmaceutical Industry Ltd Working Capital to Net Assets (2012–2025)
This chart shows how Rekah Pharmaceutical Industry Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of December 2025, the ratio stands at 56.0%, reflecting working capital of ILA80.82 Million against net assets of ILA144.21 Million ILA. Check Rekah Pharmaceutical Industry Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Rekah Pharmaceutical Industry Ltd (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Rekah Pharmaceutical Industry Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is Rekah Pharmaceutical Industry Ltd worth.
| Year | WC/NA Ratio | Working Capital (ILA) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 56.0% | ILA80.82 Million | ILA144.21 Million | ILA232.68 Million | ILA151.87 Million | ▲ +12.2 pp |
| 2024 | 43.8% | ILA71.01 Million | ILA161.98 Million | ILA229.05 Million | ILA158.04 Million | ▼ -25.3 pp |
| 2023 | 69.1% | ILA107.54 Million | ILA155.59 Million | ILA251.33 Million | ILA143.79 Million | ▲ +4.9 pp |
| 2022 | 64.2% | ILA104.11 Million | ILA162.08 Million | ILA243.14 Million | ILA139.03 Million | ▼ -6.9 pp |
| 2021 | 71.1% | ILA123.05 Million | ILA173.06 Million | ILA221.66 Million | ILA98.61 Million | ▼ -0.8 pp |
| 2020 | 71.9% | ILA119.09 Million | ILA165.59 Million | ILA227.35 Million | ILA108.26 Million | ▲ +12.0 pp |
| 2019 | 59.9% | ILA93.00 Million | ILA155.22 Million | ILA177.68 Million | ILA84.68 Million | ▼ -17.9 pp |
| 2018 | 77.9% | ILA117.30 Million | ILA150.66 Million | ILA197.15 Million | ILA79.85 Million | ▼ -1.3 pp |
| 2017 | 79.1% | ILA114.43 Million | ILA144.62 Million | ILA192.40 Million | ILA77.97 Million | ▼ -47.3 pp |
| 2016 | 126.4% | ILA133.85 Million | ILA105.86 Million | ILA226.99 Million | ILA93.14 Million | ▲ +14.8 pp |
| 2015 | 111.6% | ILA138.05 Million | ILA123.66 Million | ILA230.50 Million | ILA92.45 Million | ▼ -3.9 pp |
| 2014 | 115.5% | ILA89.03 Million | ILA77.06 Million | ILA220.72 Million | ILA131.69 Million | ▲ +87.9 pp |
| 2013 | 27.7% | ILA22.00 Million | ILA79.51 Million | ILA223.68 Million | ILA201.68 Million | ▲ +3.4 pp |
| 2012 | 24.2% | ILA17.25 Million | ILA71.17 Million | ILA213.94 Million | ILA196.69 Million | — |